IL_33及其受体ST2与动脉粥样硬化的研究进展

doi:10.3969/j.issn.1000-8535.2015.02.038

广州医药 ›› 2015, Vol. 46 ›› Issue (2): 95-96.DOI: 10.3969/j.issn.1000-8535.2015.02.038

IL_33及其受体ST2与动脉粥样硬化的研究进展

杨涛¹, 邓平², 唐嘉宇¹, 张玲玲¹

1 南华大学(衡阳 421001)
2 湖南省长沙市中心医院(长沙 410004)

收稿日期:2014-11-26 发布日期:2021-11-30

Research progress on role of the interleukin-33 and ST2 in atherosclerosis

Yang Tao, Deng Ping, Tang Jiayu, Zhang Lingling

University of South China,Hengyang 421001, China;
Changsha Central Hospital,Changsha 410004, China

Received:2014-11-26 Published:2021-11-30

摘要/Abstract

摘要： 近年来的研究已经报道证实了白细胞介素-33(IL-33)及其受体ST2可以保护心衰病人因机械应力过度牵拉所导致的心肌细胞肥大、心肌纤维化的发生以及可溶性ST2受体可作为潜在的心脏机械超负荷生物标志物。而对IL-33与受体ST2在动脉粥样硬化过程中发挥的作用少有涉及。本文主要探讨的是IL-33和ST2对抑制Th1/Th2漂移从而影响到动脉粥样硬化的进展以及血浆中可溶性ST2受体蛋白升高的意义。

关键词: 白细胞介素-33, ST2受体, Th1/Th2漂移, 动脉粥样硬化, 可溶性ST2

Abstract: Recent study has reported that interleukin-33(IL-33) and its receptor ST2 could prevent cardiomyocyte hypertrophy and exaggerated interstitial fibrosis which is because of the over harmful biomechanical force in patients with heart failure and soluble ST2 receptors is the potential biomarker of cardiac biomechanical overload. But few studies mentioned the sort of IL-33/ST2 complex plays a role in atherosclerosis. The purpose of this article is to explore the IL-33 and ST2 could reduce a Th1/Th2 shift. Consequently, it may improve the development of atherosclerosis and significance of soluble ST2 receptor increased in plasma.

Key words: Interleukin-33, ST2 receptor, Th1/Th2 shift, Atherosclerosis, Soluble ST2 receptor

杨涛, 邓平, 唐嘉宇, 张玲玲. IL_33及其受体ST2与动脉粥样硬化的研究进展[J]. 广州医药, 2015, 46(2): 95-96.

Yang Tao, Deng Ping, Tang Jiayu, Zhang Lingling. Research progress on role of the interleukin-33 and ST2 in atherosclerosis[J]. Guangzhou Medical Journal, 2015, 46(2): 95-96.

参考文献

[1] Foks AC, Lichtman AH, Kuiper J. Treating atherosclerosis with regulatory T cells[J]. Arterioscler Thrombosis Vasc Biol, 2014(114):303568.
[2] Dez J. Serum soluble ST2 as a biochemical marker of acute heart failure: future areas of research[J]. J Am Coll Cardiol,2008,52(18): 1466-1467.
[3] 向志光, 张连峰. IL-33 及其受体 ST2 的研究进展[J]. 中国比较医学杂志, 2009, 19(9): 59-62.
[4] Rehman S U, Mueller T, Januzzi JL. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure[J]. Journal of the American College of Cardiology, 2008, 52(18): 1458-1465.
[5] Wei Z, Tong B, Xia Y, et al. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 pathways[J]. PloS one, 2013, 8(3): e59171.
[6] Krishna NR, Sushma M. Pathopysolgy and pharmacotherapy of atherosclerosis[M]. 2014.
[7] Miller AM, Liew FY. The IL-33/ST2 pathway-a new therapeutic target in cardiovascular disease[J]. Pharmacology & therapeutics, 2011, 131(2): 179-186.
[8] Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger[J]. Journal of leukocyte biology, 2007, 81(1): 1-5.
[9] Taleb S, Herbin O, Ait-Oufella H, et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis[J]. Arterioscler Thrombosis Vasc Biol, 2007, 27(12): 2691-2698.
[10] Chen O, Patel J, Mohamed E, et al. The immunoregulatory role of cytokines in congestive heart failure[J]. Interdiscip J Microinflammation, 2014, 1(111): 2.
[11] Eren E, Ellidag HY, Aydin O, et al. HDL functionality and crystal-based sterile inflammation in atherosclerosis[J]. Clinica Chimica Acta, 2015,439:18-23.
[12] Pylaeva EA, Potekhina AV, Provatorov SI, et al. Effector and regulatory blood lymphocyte subpopulations in stable coronary artery disease[J]. Atherosclerosis, 2014, 235(2): e151.
[13] Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis[J]. The American journal of pathology, 2008, 172(6): 1500-1508.
[14] Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker[J]. Nature reviews Drug discovery, 2008, 7(10): 827-840.
[15] Breidthardt T, Balmelli C, Twerenbold R, et al. Heart failure therapy-Induced early ST2 changes may offer long-Term therapy guidance[J]. Journal of cardiac failure, 2013, 19(12): 821-828.
[16] Rüger K, Ottenlinger F, Schröder M, et al. Modulation of IL-33/ST2-TIR and TLR signaling pathway by fingolimod and analogs in immune cells[J]. Scandinavian journal of immunology, 2014,80(6):398-407.
[17] 刘曦. 细胞因子 IL-33 与受体相互作用的结构生物学研究[D]. 清华大学, 2013.
[18] Sattler S, Smits HH, Xu D, et al. The evolutionary role of the IL-33/ST2 system in host immune defence[J]. Archivum immunologiae et therapiae experimentalis, 2013, 61(2): 107-117.

IL_33及其受体ST2与动脉粥样硬化的研究进展

Research progress on role of the interleukin-33 and ST2 in atherosclerosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	王俊奇, 顿驭光. 复方丹参滴丸联合阿托伐他汀治疗对伴有颈动脉粥样硬化短暂性脑缺血发作患者脑循环动力的影响[J]. 广州医药, 2021, 52(1): 105-108.
[2]	宗寿健, 孙贵芝, 胡晓洁, 于丽红, 王学斌, 张金明, 王兴臣. 清化血浊中药对LAA型缺血性脑卒中的干预研究[J]. 广州医药, 2021, 52(1): 120-122.
[3]	张秀玲. 实时超声弹性成像技术评估脑卒中患者颈动脉斑块稳定性的应用研究[J]. 广州医药, 2020, 51(1): 14-18.
[4]	张秀玲, 王洁, 廖莲莲. 超声造影评价不同厚度颈动脉斑块内新生血管的临床研究[J]. 广州医药, 2018, 49(2): 46-49.
[5]	谭洁莹, 韦程纲. 急性脑卒中患者颈动脉斑块超声表现[J]. 广州医药, 2017, 48(6): 97-100.